Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
about
The effects of medications on circulating levels of cardiac natriuretic peptidesAddressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.Effects of spironolactone and losartan on the early neovascularization of acute myocardial infarction.Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current statusChronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study.The therapeutic role of RAS blockade in chronic heart failure.Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosisIndications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular riskCombination of antihypertensive drugs from a historical perspective.Treating patients for cardiovascular protection: combination therapy to achieve complete renin-angiotensin system blockade.Type 2 diabetes mellitus: prevention of macrovascular complications.Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.Angiotensin II and oxidative stress in the failing heartThe dual blockade of the renin-angiotensin system in hemodialysis patients requires decreased dialysate sodium concentrationCandesartan: widening indications for this angiotensin II receptor blocker?Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.Medication prescribing errors pertaining to cardiovascular/antidiabetic medications: a prescription audit in primary care.Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population.Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed.The one-two punch: knocking out angiotensin II in the heart.Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.Of fads, fashion, surrogate endpoints and dual RAS blockade.Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE.Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster.
P2860
Q28212913-AABFB17E-93AD-4EF3-A2F8-B3F56033320AQ33783689-38DBB4E9-8E06-40F9-B0AC-7F01E1B58FECQ33962156-8B8D72FB-F587-4D10-9E1D-8D6409EABAA9Q34124779-D2FA13F3-5410-44B0-86FF-9E95727902F4Q34543021-2901EA31-0873-40B4-BB8B-45F870F94C0FQ34915602-053FEBED-C53A-4733-9347-8A25F19F71E4Q35036184-F4E95690-C818-41EF-8AB4-EFF2C83918FDQ35539305-033BCB76-CDB2-42F1-BE12-C89601659716Q36203614-467C029C-A0F6-4630-B8A4-46EAD7DF5425Q36873154-A2351A62-B309-4FFA-8CB5-33556400196CQ37104865-D9DC02C8-ABBC-4A7E-A686-127A31FFB57FQ37158325-C83493D8-7CA1-4BC0-A6F8-74FDFFACE0E8Q37166953-2F209466-2ADF-49D2-869A-2948F34893E5Q37300713-D2AD627C-DCD6-4FEF-B656-966743C0DE93Q37534746-E3E4C713-4CCD-4629-BC43-B12E78D52F59Q37781702-1809F82A-672B-4980-9E70-02FDDB2030B5Q37832279-CBE54EF1-125C-4742-90A9-359D27D74415Q37947405-38D05954-A403-491F-AF1A-D2C008752331Q38045417-FABFCABC-E6A7-4142-9D31-1FF293CF95B9Q38048843-E1B07D20-9B17-484E-B3AA-02935A1F9439Q38076689-ABAA6DA6-348F-410B-A045-A54EF4F0540DQ39813086-80D352AF-BB0A-4786-A366-43DA8757F3B2Q41686228-2DD4C9E9-98DB-47AB-9893-8FBCFB9878B7Q42946303-157AF397-5345-4F77-A835-C0AB4F077DA3Q45263919-C2949D6B-F9AD-44FE-B9E2-1F716FF2A6B9Q45756596-F16DC102-708A-4F51-AAB6-159988E2A2B6Q46507507-39B78D95-DB0F-4472-A7A3-A2D8E87A37F5
P2860
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Effect of valsartan added to b ...... ailure: results from Val-HeFT.
@ast
Effect of valsartan added to b ...... ailure: results from Val-HeFT.
@en
Effect of valsartan added to b ...... ailure: results from Val-HeFT.
@nl
type
label
Effect of valsartan added to b ...... ailure: results from Val-HeFT.
@ast
Effect of valsartan added to b ...... ailure: results from Val-HeFT.
@en
Effect of valsartan added to b ...... ailure: results from Val-HeFT.
@nl
prefLabel
Effect of valsartan added to b ...... ailure: results from Val-HeFT.
@ast
Effect of valsartan added to b ...... ailure: results from Val-HeFT.
@en
Effect of valsartan added to b ...... ailure: results from Val-HeFT.
@nl
P2093
P2860
P1476
Effect of valsartan added to b ...... ailure: results from Val-HeFT.
@en
P2093
Aldo P Maggioni
Csaba Farsang
Jay N Cohn
Nora Aknay
Peter Carson
Robert D Glazer
Yann-Tong Chiang
P2860
P304
P356
10.1016/J.EJHEART.2004.09.005
P50
P577
2004-12-01T00:00:00Z